Fig. 4. Evaluation of the abilities of PEG-bl-DEAEMA-co-BMA nanocarriers to encapsulate therapeutic and model compounds and facilitate their intracellular delivery. Structure and molecular weight of (A) sulforhodamine-B (SRB) and (B) 2′,3′ cyclic guanosine monophosphate–adenosine monophosphate (cGAMP). (C) Encapsulation efficiency and (D) loading capacity of SRB within indicated nanocarriers. (E) MFI of MDA-MB-231 cells treated with equivalent doses of SRB as a free compound or within indicated nanocarriers overnight (mean ± SEM, n = 3–6). Analyzed via one-way ANOVA with Tukey's post-hoc. ****P < 0.0001. (F) Cytotoxicity curves of empty nanocarriers in A549 cells. (G) Encapsulation efficiency of cGAMP within indicated nanocarriers. (H) Dose response curves of STING activation following treatment with indicated cGAMP concentrations encapsulated within indicated nanocarriers. (I) Ratio of IC50 : EC50 to reflect the abilities of indicated nanocarriers to activate the STING pathway with minimal polymer-induced cytotoxicity.